42 results
DEFM14A
FUSN
Fusion Pharmaceuticals Inc
25 Apr 24
Proxy related to merger
4:13pm
of the parties, has the right to determine, direct and control the strategy and timing for and make all decisions relating to and will take the lead in all … , Fusion will use its reasonable best efforts to act consistently with such strategy, provided that, Parent consulting with, and giving reasonable
PREM14A
FUSN
Fusion Pharmaceuticals Inc
10 Apr 24
Preliminary proxy related to merger
4:42pm
of the parties, has the right to determine, direct and control the strategy and timing for and make all decisions relating to and will take the lead … permissible, Fusion will use its reasonable best efforts to act consistently with such strategy, provided that, Parent consulting with, and giving reasonable
DFAN14A
bsv87rk
19 Mar 24
Additional proxy materials by non-management
5:27pm
DEFA14A
f5x7yikfde
19 Mar 24
Additional proxy soliciting materials
6:25am
8-K
EX-2.1
ypy1 9q8xn
19 Mar 24
Voting and Support Agreement
6:24am
8-K
EX-99.1
phemdpjq
16 Oct 23
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
4:30pm
8-K
EX-99.2
ole e1l1jndi7tyto
27 Jun 23
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R
4:01pm
8-K
EX-99.1
f7qgahlyfdcdt7d7cz
8 Nov 22
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates
7:30am
8-K
EX-99.2
9enw5f4e8ud9tk
9 Jun 22
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs
7:30am